Data / Drug companies / Propranolol hydrochloride
Propranolol hydrochloride: 51 companies and 215 products in the FDA NDC directory
Propranolol hydrochloride is listed in the FDA National Drug Code Directory by 51 companies, with 215 products in commercial distribution. 201 of the products (93.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; capsule, extended release; solution, and the newest product started marketing on September 1, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 51
- Products
- 215
- Generic (ANDA) products
- 201 (93.5%)
- Application numbers
- 21
- Routes
- Oral, Intravenous
- Brand names
- Inderal La, Propranolol, Hemangeol, InnoPran XL, Inderal XL, Propranolol
- openFDA record search
- api.fda.gov
Companies that list propranolol hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 18 | tablet; capsule, extended release | Generic drugs (ANDA) | September 19, 2024 |
| Bryant Ranch Prepack | 14 | tablet; capsule, extended release | Generic drugs (ANDA) | January 6, 2020 |
| Ani Pharmaceuticals, Inc. | 12 | capsule, extended release | New drug applications (NDA) | February 22, 2018 |
| Remedyrepack Inc. | 9 | tablet; capsule, extended release | Generic drugs (ANDA) | September 9, 2025 |
| A-S Medication Solutions | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | September 19, 2024 |
| American Health Packaging | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | September 1, 2026 |
| Bryant Ranch Prepack | 8 | tablet; capsule, extended release | Generic drugs (ANDA) | March 11, 2013 |
| Preferred Pharmaceuticals Inc. | 7 | tablet | Generic drugs (ANDA) | June 10, 2026 |
| Amici Pharma, Inc. | 5 | tablet | Generic drugs (ANDA) | October 31, 2019 |
| Amneal Pharmaceuticals NY LLC | 5 | tablet | Generic drugs (ANDA) | June 3, 2021 |
| Asclemed USA, Inc. | 5 | tablet | Generic drugs (ANDA) | October 31, 2019 |
| Golden State Medical Supply, Inc. | 5 | tablet | Generic drugs (ANDA) | April 8, 2011 |
| Ipca Laboratories Limited | 5 | tablet | Generic drugs (ANDA) | September 19, 2024 |
| Lifestar Pharma LLC | 5 | tablet | Generic drugs (ANDA) | January 27, 2026 |
| Mylan Pharmaceuticals Inc. | 5 | tablet | Generic drugs (ANDA) | November 19, 1985 |
| Northwind Health Company, LLC | 5 | tablet | Generic drugs (ANDA) | February 13, 2023 |
| Par Health USA, LLC | 5 | tablet | Generic drugs (ANDA) | June 21, 2010 |
| Proficient Rx LP | 5 | tablet; capsule, extended release | Generic drugs (ANDA) | October 31, 2019 |
| Actavis Pharma, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | August 10, 2007 |
| AvKARE | 4 | capsule, extended release | Generic drugs (ANDA) | May 16, 2017 |
| Breckenridge Pharmaceutical, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | March 11, 2013 |
| Creekwood Pharmaceuticals LLC | 4 | capsule, extended release | Generic drugs (ANDA) | August 29, 2026 |
| Golden State Medical Supply, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | July 15, 2011 |
| Lannett Company, Inc. | 4 | capsule, extended release | Generic drugs (ANDA) | January 6, 2020 |
| NuCare Pharmaceuticals,Inc. | 4 | tablet | Generic drugs (ANDA) | September 19, 2024 |
| PD-Rx Pharmaceuticals, Inc. | 4 | tablet | Generic drugs (ANDA) | June 3, 2021 |
| St. Mary's Medical Park Pharmacy | 4 | capsule, extended release; tablet | Generic drugs (ANDA) | November 5, 2025 |
| Advanced Rx of Tennessee, LLC | 3 | tablet | Generic drugs (ANDA) | June 12, 2026 |
| AvPAK | 3 | tablet | Generic drugs (ANDA) | August 23, 2023 |
| Cardinal Health 107, LLC | 3 | tablet | Generic drugs (ANDA) | July 20, 2026 |
| Coupler LLC | 3 | tablet | Generic drugs (ANDA) | June 10, 2026 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 3 | tablet | Generic drugs (ANDA) | June 3, 2021 |
| Pai Holdings, LLC DBA Pai Pharma | 3 | solution | Generic drugs (ANDA) | August 19, 2026 |
| Proficient Rx LP | 3 | tablet; capsule, extended release | Generic drugs (ANDA) | September 19, 2024 |
| Aphena Pharma Solutions - Tennessee, LLC | 2 | capsule, extended release | Generic drugs (ANDA) | January 6, 2020 |
| Aphena Pharma Solutions - Tennessee, LLC | 2 | tablet | Generic drugs (ANDA) | October 31, 2019 |
| Atlantic Biologicals Corp. | 2 | solution | Generic drugs (ANDA) | May 15, 1987 |
| Direct_Rx | 2 | tablet | Generic drugs (ANDA) | February 11, 2022 |
| Hikma Pharmaceuticals USA Inc. | 2 | solution | Generic drugs (ANDA) | May 15, 1987 |
| Major Pharmaceuticals | 2 | tablet | Generic drugs (ANDA) | November 21, 2025 |
| Medical Purchasing Solutions, LLC | 2 | injection, solution; injection | Generic drugs (ANDA) | January 31, 2008 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | tablet | Generic drugs (ANDA) | November 19, 1985 |
| Eton Pharmaceuticals, Inc. | 1 | solution | New drug applications (NDA) | April 16, 2026 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | September 7, 2001 |
| Henry Schein, Inc. | 1 | injection, solution | Generic drugs (ANDA) | July 15, 2024 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection | Generic drugs (ANDA) | January 31, 2008 |
| Northwind Health Company, LLC | 1 | tablet | Generic drugs (ANDA) | August 15, 2023 |
| NuCare Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | June 21, 2010 |
| PD-Rx Pharmaceuticals, Inc. | 1 | tablet | Generic drugs (ANDA) | June 21, 2010 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | solution | New drug applications (NDA) | April 14, 2014 |
| ProPharma Distribution | 1 | injection, solution | Generic drugs (ANDA) | September 7, 2001 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 138 | 64.2% |
| Capsule, extended release | 62 | 28.8% |
| Solution | 9 | 4.2% |
| Injection, solution | 4 | 1.9% |
| Injection | 2 | 0.9% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 201 | 93.5% |
| New drug applications (NDA) | 10 | 4.7% |
| Authorized generics (NDA) | 4 | 1.9% |
Pharmacologic classes
| Class | Products |
|---|---|
| beta-Adrenergic Blocker | 215 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.